Abstract
Over the past decade, adenovirus (Ad)-based vectors have been used extensively in the context of cancer gene therapy. Two basic strategies have been pursued for the use of Ad vectors in cancer gene therapy: 1) approaches aimed at direct tumor cell killing through delivery of replicating oncolytic viruses or non-replicating vectors encoding tumor suppressor genes, suicide genes or anti-angiogenic genes, and 2) immunotherapeutic approaches aimed at inducing host antitumor immune responses that can destroy tumor cells at both primary and metastatic locations. Both strategies offer the potential of selective tumor cell destruction without damage to normal tissues. Extensive pre-clinical and clinical studies have been conducted based on these strategies. Encouraging results have been obtained but robust clinical efficacy remains elusive. Several obstacles limiting the therapeutic activity of Ad vectors have been encountered, including efficiency of tumor cell transduction and inhibition of efficacy by anti-Ad host immune responses. However, expanding knowledge in the areas of Ad biology and tumor biology continues to lead to increasingly sophisticated approaches to address these issues. A review of various Ad-based cancer gene therapy approaches and recent progress in the area are presented herein.
Keywords: Immunotherapy, tumor, vaccine, dendritic cells, suicide gene, vector, xenograft, oncolysis
Current Gene Therapy
Title: Adenovirus-Based Cancer Gene Therapy
Volume: 5 Issue: 6
Author(s): Johanne M. Kaplan
Affiliation:
Keywords: Immunotherapy, tumor, vaccine, dendritic cells, suicide gene, vector, xenograft, oncolysis
Abstract: Over the past decade, adenovirus (Ad)-based vectors have been used extensively in the context of cancer gene therapy. Two basic strategies have been pursued for the use of Ad vectors in cancer gene therapy: 1) approaches aimed at direct tumor cell killing through delivery of replicating oncolytic viruses or non-replicating vectors encoding tumor suppressor genes, suicide genes or anti-angiogenic genes, and 2) immunotherapeutic approaches aimed at inducing host antitumor immune responses that can destroy tumor cells at both primary and metastatic locations. Both strategies offer the potential of selective tumor cell destruction without damage to normal tissues. Extensive pre-clinical and clinical studies have been conducted based on these strategies. Encouraging results have been obtained but robust clinical efficacy remains elusive. Several obstacles limiting the therapeutic activity of Ad vectors have been encountered, including efficiency of tumor cell transduction and inhibition of efficacy by anti-Ad host immune responses. However, expanding knowledge in the areas of Ad biology and tumor biology continues to lead to increasingly sophisticated approaches to address these issues. A review of various Ad-based cancer gene therapy approaches and recent progress in the area are presented herein.
Export Options
About this article
Cite this article as:
Kaplan M. Johanne, Adenovirus-Based Cancer Gene Therapy, Current Gene Therapy 2005; 5 (6) . https://dx.doi.org/10.2174/156652305774964677
DOI https://dx.doi.org/10.2174/156652305774964677 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Pharmacologic Horizons in the Treatment of Benign Prostatic Hyperplasia
Current Drug Therapy Editorial [Clinical Applications of Advanced CT, MRI and Optical Imagings as Well as Spect]
Current Medical Imaging Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy
Current Cancer Drug Targets A Survey of Prostate Segmentation Techniques in Different Imaging Modalities
Current Medical Imaging Emerging Features in the Regulation of MMP-9 Gene Expression for the Development of Novel Molecular Targets and Therapeutic Strategies
Current Drug Targets - Inflammation & Allergy Analysis of the Salivary Microbiome in the Periodontal Disease Patients with Hypertension and Non-hypertension
Current Bioinformatics Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Function Analysis of Human Protein Interactions Based on a Novel Minimal Loop Algorithm
Current Bioinformatics Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry Targeting IAPs as An Approach to Anti-Cancer Therapy
Current Topics in Medicinal Chemistry Obesity and Cardiovascular Physiology: Impact of some Pharmacological Agents
Current Vascular Pharmacology Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems
Current Gene Therapy H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology New Direct and Frontal Tissue Acquisition Tools for Gene Expression Analysis in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine In Situ Gels Based Drug Delivery Systems
Current Drug Therapy Suitable Antibacterial Substances for the Treatment of Urinary Tract Infections
Anti-Infective Agents in Medicinal Chemistry Anticancer and Cytotoxic Activities of [Cu(C6H16N2O2)2][Ni(CN)4] and [Cu(C6H16N2O2)Pd(CN)4] Cyanidometallate Compounds on HT29, HeLa, C6 and Vero Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges
Current Medicinal Chemistry Opportunities for Photoacoustic-Guided Drug Delivery
Current Drug Targets Anti-inflammatory Action of Green Tea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry